| Alan Weisberg, DPM | |
|
50 Berkshire Ct, Wyomissing, PA 19610-1219 | |
| (610) 373-4154 | |
| (610) 373-4155 |
| Full Name | Alan Weisberg |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 38 Years |
| Location | 50 Berkshire Ct, Wyomissing, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134118896 | NPI | - | NPPES |
| 0015089130003 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | SC003047L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reading Hospital | West reading, PA | Hospital |
| Surgical Institute Of Reading | Wyomissing, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Foot And Ankle Specialists Of Pa Llc | 1153704754 | 19 |
News Archive
With a five-year, $3 million R01 award from the National Institutes of Health, through the National Cancer Institute, a team of researchers led by Gregory Fischer, PhD, assistant professor of mechanical engineering and robotics engineering at Worcester Polytechnic Institute and director of WPI's Automation and Interventional Medicine Laboratory, will test a new, minimally invasive approach to treating brain tumors that promises to accurately destroy malignant tissue while leaving surrounding tissue unaffected.
Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186).
In speeches from the podium and in the buzz from the convention floor, it was apparent on the first day of the Democratic National Convention that delegates and speakers aimed to reclaim the health law as an important accomplishment of the Obama administration.
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.
› Verified 1 days ago
| Provider Name | Berkshire Podiatry Center Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780622217 PECOS PAC ID: 0547245003 Enrollment ID: O20040621000549 |
News Archive
With a five-year, $3 million R01 award from the National Institutes of Health, through the National Cancer Institute, a team of researchers led by Gregory Fischer, PhD, assistant professor of mechanical engineering and robotics engineering at Worcester Polytechnic Institute and director of WPI's Automation and Interventional Medicine Laboratory, will test a new, minimally invasive approach to treating brain tumors that promises to accurately destroy malignant tissue while leaving surrounding tissue unaffected.
Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186).
In speeches from the podium and in the buzz from the convention floor, it was apparent on the first day of the Democratic National Convention that delegates and speakers aimed to reclaim the health law as an important accomplishment of the Obama administration.
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.
› Verified 1 days ago
| Provider Name | Integrated Foot And Ankle Specialists Of Pa Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588311625 PECOS PAC ID: 1153704754 Enrollment ID: O20220815002056 |
News Archive
With a five-year, $3 million R01 award from the National Institutes of Health, through the National Cancer Institute, a team of researchers led by Gregory Fischer, PhD, assistant professor of mechanical engineering and robotics engineering at Worcester Polytechnic Institute and director of WPI's Automation and Interventional Medicine Laboratory, will test a new, minimally invasive approach to treating brain tumors that promises to accurately destroy malignant tissue while leaving surrounding tissue unaffected.
Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186).
In speeches from the podium and in the buzz from the convention floor, it was apparent on the first day of the Democratic National Convention that delegates and speakers aimed to reclaim the health law as an important accomplishment of the Obama administration.
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alan Weisberg, DPM 50 Berkshire Ct, Wyomissing, PA 19610-1219 Ph: (610) 373-4154 | Alan Weisberg, DPM 50 Berkshire Ct, Wyomissing, PA 19610-1219 Ph: (610) 373-4154 |
News Archive
With a five-year, $3 million R01 award from the National Institutes of Health, through the National Cancer Institute, a team of researchers led by Gregory Fischer, PhD, assistant professor of mechanical engineering and robotics engineering at Worcester Polytechnic Institute and director of WPI's Automation and Interventional Medicine Laboratory, will test a new, minimally invasive approach to treating brain tumors that promises to accurately destroy malignant tissue while leaving surrounding tissue unaffected.
Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186).
In speeches from the podium and in the buzz from the convention floor, it was apparent on the first day of the Democratic National Convention that delegates and speakers aimed to reclaim the health law as an important accomplishment of the Obama administration.
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and secondary endpoints of the clinical trial.
› Verified 1 days ago
David Peter Bartos, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 320 Abington Dr, Wyomissing, PA 19610 Phone: 610-670-2277 Fax: 610-670-5246 | |
Wyomissing Podiatry Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 916 Penn Ave, Wyomissing, PA 19610 Phone: 610-376-5649 Fax: 610-376-4194 | |
Reading Surgery Center Of The Surgical Institute Of Reading, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 2752 Century Blvd, Wyomissing, PA 19610 Phone: 610-378-8800 Fax: 610-372-7429 | |
Premier Foot & Ankle Associates Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 320 Abington Dr, Wyomissing, PA 19610 Phone: 610-670-2277 Fax: 610-670-5246 | |
Dr. James Nicholas Pace, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 916 Penn Ave, Wyomissing, PA 19610 Phone: 610-376-5649 Fax: 610-376-4194 | |
I E Schifalacqua, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 50 Berkshire Ct, Wyomissing, PA 19610 Phone: 610-373-4154 Fax: 610-373-8651 |